IN191534B - - Google Patents

Info

Publication number
IN191534B
IN191534B IN357BO2001A IN191534B IN 191534 B IN191534 B IN 191534B IN 357BO2001 A IN357BO2001 A IN 357BO2001A IN 191534 B IN191534 B IN 191534B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Joseph Philip Rainville
Terry Gene Sinay Jr
Stanley Walter Walinsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IN191534B publication Critical patent/IN191534B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IN357BO2001 2000-04-28 2001-04-20 IN191534B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20041700P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
IN191534B true IN191534B (es) 2003-12-06

Family

ID=22741639

Family Applications (1)

Application Number Title Priority Date Filing Date
IN357BO2001 IN191534B (es) 2000-04-28 2001-04-20

Country Status (26)

Country Link
US (1) US6570018B2 (es)
EP (1) EP1149831B1 (es)
JP (1) JP2001354650A (es)
KR (1) KR100432841B1 (es)
CN (1) CN1211366C (es)
AR (1) AR028377A1 (es)
AT (1) ATE275130T1 (es)
AU (1) AU781715B2 (es)
BR (1) BR0101611A (es)
CA (1) CA2345286C (es)
CZ (1) CZ20011472A3 (es)
DE (1) DE60105221T2 (es)
DK (1) DK1149831T3 (es)
ES (1) ES2225425T3 (es)
HK (1) HK1040514B (es)
HU (1) HUP0101725A3 (es)
ID (1) ID30012A (es)
IL (1) IL142706A0 (es)
IN (1) IN191534B (es)
PL (1) PL347299A1 (es)
PT (1) PT1149831E (es)
RU (1) RU2192415C1 (es)
SI (1) SI1149831T1 (es)
TW (1) TWI222440B (es)
YU (1) YU27801A (es)
ZA (1) ZA200103321B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN105037221B (zh) * 2015-06-18 2017-05-10 吉林大学珠海学院 一种具有神经保护作用的化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59341C2 (uk) 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
CZ20011472A3 (cs) 2001-12-12
EP1149831A1 (en) 2001-10-31
HUP0101725A3 (en) 2003-04-28
DE60105221T2 (de) 2005-09-15
AU781715B2 (en) 2005-06-09
YU27801A (sh) 2003-04-30
CA2345286A1 (en) 2001-10-28
KR100432841B1 (ko) 2004-05-24
US6570018B2 (en) 2003-05-27
EP1149831B1 (en) 2004-09-01
DK1149831T3 (da) 2004-12-06
PL347299A1 (en) 2001-11-05
AU3889701A (en) 2001-12-13
CN1322716A (zh) 2001-11-21
ID30012A (id) 2001-11-01
CN1211366C (zh) 2005-07-20
ATE275130T1 (de) 2004-09-15
PT1149831E (pt) 2004-11-30
JP2001354650A (ja) 2001-12-25
HK1040514A1 (en) 2002-06-14
HUP0101725A2 (hu) 2002-02-28
KR20010098924A (ko) 2001-11-08
RU2192415C1 (ru) 2002-11-10
CA2345286C (en) 2004-11-09
BR0101611A (pt) 2002-01-15
ES2225425T3 (es) 2005-03-16
AR028377A1 (es) 2003-05-07
SI1149831T1 (en) 2005-02-28
IL142706A0 (en) 2002-03-10
TWI222440B (en) 2004-10-21
HK1040514B (zh) 2005-10-28
HU0101725D0 (en) 2001-07-30
US20020016466A1 (en) 2002-02-07
ZA200103321B (en) 2002-10-24
DE60105221D1 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
BE2016C059I2 (es)
BE2014C035I2 (es)
BE2014C019I2 (es)
BE2014C009I2 (es)
BE2011C041I2 (es)
BE2010C018I2 (es)
BE2010C019I2 (es)
JP2003514178A5 (es)
BE2009C057I2 (es)
BRPI0112928B8 (es)
AR028236A3 (es)
AU2000236813A8 (es)
JP2001250956A5 (es)
IN191480B (es)
JP2001324556A5 (es)
JP2002031215A5 (es)
IN192890B (es)
JP2003515727A5 (es)
JP2003508852A5 (es)
JP2002147360A5 (es)
IN191534B (es)
JP2001198371A5 (es)
BRPI0003419A (es)
JP2001276027A5 (es)
JP2002120304A5 (es)